{"id":346356,"date":"2025-08-25T10:06:42","date_gmt":"2025-08-25T10:06:42","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-exelixis\/"},"modified":"2025-08-25T10:06:42","modified_gmt":"2025-08-25T10:06:42","slug":"how-to-buy-exelixis","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/","title":{"rendered":"Exelixis, Inc. (EXEL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Exelixis, Inc. (EXEL) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334099,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-346356","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Exelixis, Inc. (EXEL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Exelixis, Inc. (EXEL) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Exelixis, Inc. (EXEL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Exelixis, Inc. (EXEL) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Exelixis, Inc. (EXEL) hisselerini nas\u0131l alaca\u011f\u0131n\u0131z\u0131 kapsaml\u0131 yat\u0131r\u0131m analizimizle \u00f6\u011frenin. Bu onkoloji odakl\u0131 biyoteknoloji \u015firketinin g\u00fcncel hisse performans\u0131n\u0131, b\u00fcy\u00fcme tahminlerini ve ticaret stratejilerini ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Exelixis, Inc. (EXEL) hisselerini nas\u0131l alaca\u011f\u0131n\u0131z\u0131 kapsaml\u0131 yat\u0131r\u0131m analizimizle \u00f6\u011frenin. Bu onkoloji odakl\u0131 biyoteknoloji \u015firketinin g\u00fcncel hisse performans\u0131n\u0131, b\u00fcy\u00fcme tahminlerini ve ticaret stratejilerini ke\u015ffedin."},"intro":"Kanserle m\u00fccadele eden ve ayn\u0131 zamanda servetinizi b\u00fcy\u00fctme potansiyeline sahip bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Exelixis, Inc. (EXEL) tam da bu f\u0131rsat\u0131 temsil ediyor. Bu yenilik\u00e7i biyoteknoloji firmas\u0131 onkoloji tedavilerinde \u00f6nemli geli\u015fmeler kaydetti ve hisseleri de\u011fer ile b\u00fcy\u00fcme potansiyelinin ilgin\u00e7 bir kar\u0131\u015f\u0131m\u0131n\u0131 sunuyor. EXEL'in neden dikkatinizi hak etti\u011fini ve onlar\u0131n yolculu\u011funun bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Kanserle m\u00fccadele eden ve ayn\u0131 zamanda servetinizi b\u00fcy\u00fctme potansiyeline sahip bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Exelixis, Inc. (EXEL) tam da bu f\u0131rsat\u0131 temsil ediyor. Bu yenilik\u00e7i biyoteknoloji firmas\u0131 onkoloji tedavilerinde \u00f6nemli geli\u015fmeler kaydetti ve hisseleri de\u011fer ile b\u00fcy\u00fcme potansiyelinin ilgin\u00e7 bir kar\u0131\u015f\u0131m\u0131n\u0131 sunuyor. EXEL'in neden dikkatinizi hak etti\u011fini ve onlar\u0131n yolculu\u011funun bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa G\u00f6r\u00fcn\u00fcm\u00fc ve Ticaret Dinamikleri<\/h2> <p>25 A\u011fustos 2025 itibar\u0131yla Exelixis, Inc. (EXEL) NASDAQ borsas\u0131nda <strong>38,63 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Hisse senedi, son piyasa dalgalanmalar\u0131na ra\u011fmen 200 g\u00fcnl\u00fck hareketli ortalamas\u0131 olan 37,90 $ seviyesinin \u00fczerinde g\u00fc\u00e7l\u00fc bir konumunu koruyarak dikkat \u00e7ekici bir diren\u00e7 g\u00f6sterdi.<\/p> <p><strong>Takviminize not edin: 28 Ekim 2025<\/strong>, EXEL yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in bir sonraki kritik tarih. \u015eirketin 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayaca\u011f\u0131 g\u00fcn bu. Tarihsel olarak, bu a\u00e7\u0131klamalar \u00f6nemli fiyat hareketlerine - hem yukar\u0131 hem a\u015fa\u011f\u0131 - neden olmu\u015ftur.<\/p> <h3>Kazan\u00e7 Raporlar\u0131 EXEL Hissesini Nas\u0131l Etkiler?<\/h3> <p>Son tarihleri inceledi\u011fimizde net bir desen ortaya \u00e7\u0131k\u0131yor. 2025 2. \u00e7eyre\u011finde (28 Temmuz) EXEL, beklenen 0,61 $ EPS'ye kar\u015f\u0131l\u0131k <strong>%22,95<\/strong> gibi muazzam bir kazan\u00e7 s\u00fcrprizi yaparak 0,75 $ EPS bildirdi. Bu olumlu s\u00fcrprize ra\u011fmen, gelir beklentilerinin biraz alt\u0131nda kalmas\u0131 nedeniyle hisse \u00fczerinde bir miktar bask\u0131 olu\u015ftu.<\/p> <p>2025 1. \u00e7eyrek sonu\u00e7lar\u0131 daha da etkileyiciydi - 0,44 $ tahminine kar\u015f\u0131l\u0131k 0,62 $ EPS ile <strong>%40,91<\/strong> kazan\u00e7 s\u00fcrprizi. Bu tutarl\u0131 a\u015fma deseni g\u00fc\u00e7l\u00fc operasyonel uygulamay\u0131 g\u00f6steriyor, ancak piyasa bazen gelir metriklerine daha fazla odaklanabiliyor.<\/p> <h3>6 Ayl\u0131k Fiyat Yolculu\u011fu (Mart-A\u011fustos 2025)<\/h3> <p>EXEL son alt\u0131 ayda ilgin\u00e7 bir yol izledi:<\/p> <ul> <li><strong>Mart 2025<\/strong>: Piyasa 1. \u00e7eyrek sonu\u00e7lar\u0131n\u0131 beklerken 33-35 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rd\u00fc<\/li> <li><strong>Nisan 2025<\/strong>: G\u00fc\u00e7l\u00fc 1. \u00e7eyrek kazan\u00e7lar\u0131 ve n\u00f6roendokrin t\u00fcm\u00f6rler i\u00e7in FDA onay\u0131 sonras\u0131 38-40 $ aral\u0131\u011f\u0131na s\u0131\u00e7rama<\/li> <li><strong>Haziran 2025<\/strong>: Yeni endikasyon lansman\u0131n\u0131 sindirirken 41-42 $ civar\u0131nda konsolidasyon<\/li> <li><strong>Temmuz 2025<\/strong>: Kazan\u00e7 s\u00fcrprizine ra\u011fmen 2. \u00e7eyrek sonras\u0131 38-39 $ seviyelerine geri \u00e7ekilme<\/li> <li><strong>A\u011fustos 2025<\/strong>: Artan volatilite ile 38,63 $ seviyesinde mevcut stabilizasyon<\/li> <\/ul> <p>Genel trend, sekt\u00f6r zorluklar\u0131na ra\u011fmen <strong>y\u0131lba\u015f\u0131ndan bu yana yakla\u015f\u0131k %15 b\u00fcy\u00fcme<\/strong> g\u00f6stererek hissenin yukar\u0131 y\u00f6nl\u00fc ivmesini koruma yetene\u011fini ortaya koyuyor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve piyasa ko\u015fullar\u0131na dayanarak, EXEL i\u00e7in gelecekte neler olabilece\u011fine dair \u00f6ng\u00f6r\u00fcler:<\/p> <p><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: 41-44 $ aral\u0131\u011f\u0131 (mevcut seviyelerden %6-14 yukar\u0131 potansiyel)<br\/> Analistler \"Al\" notunu koruyor ve ortalama fiyat hedefi 43,65 $ <a href=\"https:\/\/public.com\/stocks\/exel\/forecast-price-target\">Public.com Analizi<\/a><\/p> <p><strong>2026 Projeksiyonu<\/strong>: 45-50 $ aral\u0131\u011f\u0131<br\/> Geni\u015fleyen endikasyonlar ve \u00fcr\u00fcn hatt\u0131 geli\u015fmeleriyle devam eden b\u00fcy\u00fcme<\/p> <p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 55-65 $ aral\u0131\u011f\u0131<br\/> Piyasaya ula\u015fan yeni \u00fcr\u00fcn adaylar\u0131ndan potansiyel at\u0131l\u0131m<\/p> <p><strong>2030 Vizyonu<\/strong>: 70-85 $ aral\u0131\u011f\u0131<br\/> \u00c7e\u015fitlendirilmi\u015f portf\u00f6y ile hedefe y\u00f6nelik onkoloji tedavilerinde pazar liderli\u011fi<\/p> <p><strong>Sonu\u00e7<\/strong>: Uzun vadeli b\u00fcy\u00fcme i\u00e7in AL, ancak volatilite nedeniyle dolar maliyeti ortalamas\u0131 yapmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/p> <h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2> <h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3> <ul> <li><strong>Reg\u00fclasyon belirsizli\u011fi<\/strong>: FDA onaylar\u0131 \u00f6ng\u00f6r\u00fclemez olabilir<\/li> <li><strong>Rekabet bask\u0131s\u0131<\/strong>: S\u00fcrekli piyasaya yeni kanser ila\u00e7lar\u0131 giriyor<\/li> <li><strong>Gelir yo\u011funla\u015fmas\u0131<\/strong>: \u00dcr\u00fcn gelirlerinin %95'inden fazlas\u0131 Cabometyx'e ba\u011fl\u0131<\/li> <li><strong>Ortakl\u0131k dalgalanmalar\u0131<\/strong>: Ortakl\u0131k gelirleri \u00e7eyrekten \u00e7eyre\u011fe \u00f6nemli \u00f6l\u00e7\u00fcde de\u011fi\u015febilir<\/li> <\/ul> <h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3> <ul> <li><strong>Yeni endikasyon ba\u015far\u0131s\u0131<\/strong>: N\u00f6roendokrin t\u00fcm\u00f6r onay\u0131 i\u015fin %4'\u00fcn\u00fc \u015fimdiden yakalad\u0131<\/li> <li><strong>G\u00fc\u00e7l\u00fc finansallar<\/strong>: %29 \u00f6z sermaye getirisi ve 638 milyon $ serbest nakit ak\u0131\u015f\u0131<\/li> <li><strong>\u00dcr\u00fcn hatt\u0131 ilerlemesi<\/strong>: Zanzalintinib dahil bir\u00e7ok aday geli\u015ftirme a\u015famas\u0131nda<\/li> <li><strong>Analist deste\u011fi<\/strong>: 20 analist \"Al\" notu verirken \"Sat\" \u00f6nerisi yok<\/li> <li><strong>Kazan\u00e7 tutarl\u0131l\u0131\u011f\u0131<\/strong>: Son d\u00f6rt \u00e7eyrekte ortalama %48,6 kazan\u00e7 s\u00fcrprizi<\/li> <\/ul> <h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2> <ol> <li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> - Portf\u00f6y\u00fcn\u00fcz\u00fcn %1-2'si kadar ilk pozisyon d\u00fc\u015f\u00fcn\u00fcn<\/li> <li><strong>Fiyat uyar\u0131lar\u0131 kurun<\/strong> - Potansiyel giri\u015f noktalar\u0131 i\u00e7in 28 Ekim kazan\u00e7 tarihini izleyin<\/li> <li><strong>Uzun vadeli d\u00fc\u015f\u00fcn\u00fcn<\/strong> - Biyoteknoloji yat\u0131r\u0131mlar\u0131 genellikle klinik denemeler boyunca sab\u0131r gerektirir<\/li> <li><strong>\u00c7e\u015fitlendirin<\/strong> - T\u00fcm biyoteknoloji pay\u0131n\u0131z\u0131 tek bir \u015firkete yat\u0131rmay\u0131n<\/li> <\/ol> <p>Esprili t\u00fcccar bilgeli\u011fi: \"EXEL ticareti yapmak, kanser ara\u015ft\u0131rmas\u0131n\u0131 izlemek gibidir - bazen at\u0131l\u0131m\u0131 beklemeniz gerekir, ama geldi\u011finde sabretmeye de\u011fer!\"<\/p> <h2>\u2705 Exelixis, Inc. (EXEL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Bir ticaret platformu se\u00e7in<\/td><td>NASDAQ listelerini ve makul \u00fccretleri sundu\u011fundan emin olun<\/td><\/tr> <tr><td>2<\/td><td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td><td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>EXEL'i kapsaml\u0131 ara\u015ft\u0131r\u0131n<\/td><td>\u015eirketin \u00fcr\u00fcnlerini ve \u00fcr\u00fcn hatt\u0131n\u0131 anlay\u0131n<\/td><\/tr> <tr><td>4<\/td><td>Sipari\u015f t\u00fcr\u00fcn\u00fcz\u00fc belirleyin<\/td><td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td><\/tr> <tr><td>5<\/td><td>Yat\u0131r\u0131m\u0131n\u0131z\u0131 izleyin<\/td><td>Biyoteknoloji haberlerine s\u00fcrekli dikkat gerektirir<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Cazip?<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa yeni ba\u015flayanlar i\u00e7in Pocket Option, borsaya giri\u015fin daha az korkutucu olmas\u0131n\u0131 sa\u011flayan birka\u00e7 avantaj sunar:<\/p> <p><strong>Sadece 5 $ minimum depozito<\/strong> ile stratejileri d\u00fc\u015f\u00fck riskle test etmenize olanak tan\u0131r. Bu, fiyatlar\u0131n \u00f6nemli dalgalanmalar g\u00f6sterebildi\u011fi biyoteknoloji gibi volatil sekt\u00f6rler i\u00e7in \u00f6zellikle de\u011ferlidir.<\/p> <p><strong>H\u0131zl\u0131 do\u011frulama s\u00fcreci<\/strong> sayesinde hesap a\u00e7\u0131ld\u0131ktan sonra dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flayabilirsiniz. Platform, \u00e7ok \u00e7e\u015fitli kimlik belgelerini kabul ederek eri\u015filebilirli\u011fi \u00f6nceliklendirir.<\/p> <p><strong>\u00c7oklu para \u00e7ekme se\u00e7enekleri<\/strong> aras\u0131nda banka transferleri, e-c\u00fczdanlar ve kripto para bulunur; bu da karlar\u0131n\u0131za eri\u015fimde esneklik sa\u011flar. Tercih etti\u011finiz \u00f6deme y\u00f6ntemi ne olursa olsun uygun se\u00e7enekler bulabilirsiniz.<\/p> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ve e\u011fitim kaynaklar\u0131, \u00f6zellikle biyoteknoloji gibi karma\u015f\u0131k sekt\u00f6rlerle u\u011fra\u015f\u0131rken \u00f6\u011frenirken kazanmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir.<\/p> <h2>\ud83c\udf0d 2025'te Exelixis: Onkoloji \u0130novasyon Lideri<\/h2> <p>Exelixis, kanser tedavisi alan\u0131nda \u00f6nemli bir oyuncu olarak kendini kan\u0131tlad\u0131. \u015eirketin hedefe y\u00f6nelik k\u00fc\u00e7\u00fck molek\u00fcl tedavilerine odaklanmas\u0131 ba\u015far\u0131l\u0131 oldu, \u00f6zellikle \u00e7oklu kanser t\u00fcrlerini tedavi eden amiral gemisi ilac\u0131 Cabometyx ile; b\u00f6brek h\u00fccreli karsinom, karaci\u011fer kanseri ve \u015fimdi de n\u00f6roendokrin t\u00fcm\u00f6rler dahil.<\/p> <p>\u015eirketin i\u015f modeli, do\u011frudan \u00fcr\u00fcn sat\u0131\u015flar\u0131n\u0131 Ipsen ve Takeda gibi b\u00fcy\u00fck ila\u00e7 \u015firketleriyle stratejik ortakl\u0131klarla birle\u015ftiriyor. Bu yakla\u015f\u0131m, daha b\u00fcy\u00fck \u015firketlerin da\u011f\u0131t\u0131m a\u011flar\u0131ndan yararlan\u0131rken ara\u015ft\u0131rma ve geli\u015ftirmeye odaklanmalar\u0131n\u0131 sa\u011fl\u0131yor.<\/p> <p><strong>2025 i\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Exelixis, Amerika Birle\u015fik Devletleri genelinde <strong>214 kapsaml\u0131 kanser merkezi<\/strong> ile etkileyici bir i\u015f birli\u011fi a\u011f\u0131na sahip; bunlar\u0131n aras\u0131nda 51 Ulusal Kanser Enstit\u00fcs\u00fc taraf\u0131ndan belirlenmi\u015f merkez bulunuyor. \u0130la\u00e7lar\u0131, 87 akademik t\u0131p merkezi ve 129 toplum hastanesi a\u011f\u0131 arac\u0131l\u0131\u011f\u0131yla hastalara ula\u015f\u0131yor; bu, orta \u00f6l\u00e7ekli bir biyoteknoloji \u015firketi i\u00e7in inan\u0131lmaz bir pazar penetrasyonunu g\u00f6steriyor.<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Piyasa G\u00f6r\u00fcn\u00fcm\u00fc ve Ticaret Dinamikleri<\/h2>\n<p>25 A\u011fustos 2025 itibar\u0131yla Exelixis, Inc. (EXEL) NASDAQ borsas\u0131nda <strong>38,63 $<\/strong> seviyesinde i\u015flem g\u00f6r\u00fcyor. Hisse senedi, son piyasa dalgalanmalar\u0131na ra\u011fmen 200 g\u00fcnl\u00fck hareketli ortalamas\u0131 olan 37,90 $ seviyesinin \u00fczerinde g\u00fc\u00e7l\u00fc bir konumunu koruyarak dikkat \u00e7ekici bir diren\u00e7 g\u00f6sterdi.<\/p>\n<p><strong>Takviminize not edin: 28 Ekim 2025<\/strong>, EXEL yat\u0131r\u0131mc\u0131lar\u0131 i\u00e7in bir sonraki kritik tarih. \u015eirketin 3. \u00e7eyrek kazan\u00e7 raporunu a\u00e7\u0131klayaca\u011f\u0131 g\u00fcn bu. Tarihsel olarak, bu a\u00e7\u0131klamalar \u00f6nemli fiyat hareketlerine &#8211; hem yukar\u0131 hem a\u015fa\u011f\u0131 &#8211; neden olmu\u015ftur.<\/p>\n<h3>Kazan\u00e7 Raporlar\u0131 EXEL Hissesini Nas\u0131l Etkiler?<\/h3>\n<p>Son tarihleri inceledi\u011fimizde net bir desen ortaya \u00e7\u0131k\u0131yor. 2025 2. \u00e7eyre\u011finde (28 Temmuz) EXEL, beklenen 0,61 $ EPS&#8217;ye kar\u015f\u0131l\u0131k <strong>%22,95<\/strong> gibi muazzam bir kazan\u00e7 s\u00fcrprizi yaparak 0,75 $ EPS bildirdi. Bu olumlu s\u00fcrprize ra\u011fmen, gelir beklentilerinin biraz alt\u0131nda kalmas\u0131 nedeniyle hisse \u00fczerinde bir miktar bask\u0131 olu\u015ftu.<\/p>\n<p>2025 1. \u00e7eyrek sonu\u00e7lar\u0131 daha da etkileyiciydi &#8211; 0,44 $ tahminine kar\u015f\u0131l\u0131k 0,62 $ EPS ile <strong>%40,91<\/strong> kazan\u00e7 s\u00fcrprizi. Bu tutarl\u0131 a\u015fma deseni g\u00fc\u00e7l\u00fc operasyonel uygulamay\u0131 g\u00f6steriyor, ancak piyasa bazen gelir metriklerine daha fazla odaklanabiliyor.<\/p>\n<h3>6 Ayl\u0131k Fiyat Yolculu\u011fu (Mart-A\u011fustos 2025)<\/h3>\n<p>EXEL son alt\u0131 ayda ilgin\u00e7 bir yol izledi:<\/p>\n<ul>\n<li><strong>Mart 2025<\/strong>: Piyasa 1. \u00e7eyrek sonu\u00e7lar\u0131n\u0131 beklerken 33-35 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rd\u00fc<\/li>\n<li><strong>Nisan 2025<\/strong>: G\u00fc\u00e7l\u00fc 1. \u00e7eyrek kazan\u00e7lar\u0131 ve n\u00f6roendokrin t\u00fcm\u00f6rler i\u00e7in FDA onay\u0131 sonras\u0131 38-40 $ aral\u0131\u011f\u0131na s\u0131\u00e7rama<\/li>\n<li><strong>Haziran 2025<\/strong>: Yeni endikasyon lansman\u0131n\u0131 sindirirken 41-42 $ civar\u0131nda konsolidasyon<\/li>\n<li><strong>Temmuz 2025<\/strong>: Kazan\u00e7 s\u00fcrprizine ra\u011fmen 2. \u00e7eyrek sonras\u0131 38-39 $ seviyelerine geri \u00e7ekilme<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: Artan volatilite ile 38,63 $ seviyesinde mevcut stabilizasyon<\/li>\n<\/ul>\n<p>Genel trend, sekt\u00f6r zorluklar\u0131na ra\u011fmen <strong>y\u0131lba\u015f\u0131ndan bu yana yakla\u015f\u0131k %15 b\u00fcy\u00fcme<\/strong> g\u00f6stererek hissenin yukar\u0131 y\u00f6nl\u00fc ivmesini koruma yetene\u011fini ortaya koyuyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve piyasa ko\u015fullar\u0131na dayanarak, EXEL i\u00e7in gelecekte neler olabilece\u011fine dair \u00f6ng\u00f6r\u00fcler:<\/p>\n<p><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: 41-44 $ aral\u0131\u011f\u0131 (mevcut seviyelerden %6-14 yukar\u0131 potansiyel)<br \/> Analistler &#8220;Al&#8221; notunu koruyor ve ortalama fiyat hedefi 43,65 $ <a href=\"https:\/\/public.com\/stocks\/exel\/forecast-price-target\">Public.com Analizi<\/a><\/p>\n<p><strong>2026 Projeksiyonu<\/strong>: 45-50 $ aral\u0131\u011f\u0131<br \/> Geni\u015fleyen endikasyonlar ve \u00fcr\u00fcn hatt\u0131 geli\u015fmeleriyle devam eden b\u00fcy\u00fcme<\/p>\n<p><strong>2028 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 55-65 $ aral\u0131\u011f\u0131<br \/> Piyasaya ula\u015fan yeni \u00fcr\u00fcn adaylar\u0131ndan potansiyel at\u0131l\u0131m<\/p>\n<p><strong>2030 Vizyonu<\/strong>: 70-85 $ aral\u0131\u011f\u0131<br \/> \u00c7e\u015fitlendirilmi\u015f portf\u00f6y ile hedefe y\u00f6nelik onkoloji tedavilerinde pazar liderli\u011fi<\/p>\n<p><strong>Sonu\u00e7<\/strong>: Uzun vadeli b\u00fcy\u00fcme i\u00e7in AL, ancak volatilite nedeniyle dolar maliyeti ortalamas\u0131 yapmay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/p>\n<h2>\u26a0\ufe0f Temel Riskler ve Olumlu \u0130\u015faretler<\/h2>\n<h3>Dikkate Al\u0131nmas\u0131 Gereken Riskler<\/h3>\n<ul>\n<li><strong>Reg\u00fclasyon belirsizli\u011fi<\/strong>: FDA onaylar\u0131 \u00f6ng\u00f6r\u00fclemez olabilir<\/li>\n<li><strong>Rekabet bask\u0131s\u0131<\/strong>: S\u00fcrekli piyasaya yeni kanser ila\u00e7lar\u0131 giriyor<\/li>\n<li><strong>Gelir yo\u011funla\u015fmas\u0131<\/strong>: \u00dcr\u00fcn gelirlerinin %95&#8217;inden fazlas\u0131 Cabometyx&#8217;e ba\u011fl\u0131<\/li>\n<li><strong>Ortakl\u0131k dalgalanmalar\u0131<\/strong>: Ortakl\u0131k gelirleri \u00e7eyrekten \u00e7eyre\u011fe \u00f6nemli \u00f6l\u00e7\u00fcde de\u011fi\u015febilir<\/li>\n<\/ul>\n<h3>2025-2026 \u0130\u00e7in Ye\u015fil I\u015f\u0131klar<\/h3>\n<ul>\n<li><strong>Yeni endikasyon ba\u015far\u0131s\u0131<\/strong>: N\u00f6roendokrin t\u00fcm\u00f6r onay\u0131 i\u015fin %4&#8217;\u00fcn\u00fc \u015fimdiden yakalad\u0131<\/li>\n<li><strong>G\u00fc\u00e7l\u00fc finansallar<\/strong>: %29 \u00f6z sermaye getirisi ve 638 milyon $ serbest nakit ak\u0131\u015f\u0131<\/li>\n<li><strong>\u00dcr\u00fcn hatt\u0131 ilerlemesi<\/strong>: Zanzalintinib dahil bir\u00e7ok aday geli\u015ftirme a\u015famas\u0131nda<\/li>\n<li><strong>Analist deste\u011fi<\/strong>: 20 analist &#8220;Al&#8221; notu verirken &#8220;Sat&#8221; \u00f6nerisi yok<\/li>\n<li><strong>Kazan\u00e7 tutarl\u0131l\u0131\u011f\u0131<\/strong>: Son d\u00f6rt \u00e7eyrekte ortalama %48,6 kazan\u00e7 s\u00fcrprizi<\/li>\n<\/ul>\n<h2>\ud83d\udee1\ufe0f Yeni Ba\u015flayan Bir T\u00fcccar Bug\u00fcn Ne Yapmal\u0131?<\/h2>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck ba\u015flay\u0131n<\/strong> &#8211; Portf\u00f6y\u00fcn\u00fcz\u00fcn %1-2&#8217;si kadar ilk pozisyon d\u00fc\u015f\u00fcn\u00fcn<\/li>\n<li><strong>Fiyat uyar\u0131lar\u0131 kurun<\/strong> &#8211; Potansiyel giri\u015f noktalar\u0131 i\u00e7in 28 Ekim kazan\u00e7 tarihini izleyin<\/li>\n<li><strong>Uzun vadeli d\u00fc\u015f\u00fcn\u00fcn<\/strong> &#8211; Biyoteknoloji yat\u0131r\u0131mlar\u0131 genellikle klinik denemeler boyunca sab\u0131r gerektirir<\/li>\n<li><strong>\u00c7e\u015fitlendirin<\/strong> &#8211; T\u00fcm biyoteknoloji pay\u0131n\u0131z\u0131 tek bir \u015firkete yat\u0131rmay\u0131n<\/li>\n<\/ol>\n<p>Esprili t\u00fcccar bilgeli\u011fi: &#8220;EXEL ticareti yapmak, kanser ara\u015ft\u0131rmas\u0131n\u0131 izlemek gibidir &#8211; bazen at\u0131l\u0131m\u0131 beklemeniz gerekir, ama geldi\u011finde sabretmeye de\u011fer!&#8221;<\/p>\n<h2>\u2705 Exelixis, Inc. (EXEL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir ticaret platformu se\u00e7in<\/td>\n<td>NASDAQ listelerini ve makul \u00fccretleri sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesab\u0131n\u0131z\u0131 a\u00e7\u0131n ve fonlay\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>EXEL&#8217;i kapsaml\u0131 ara\u015ft\u0131r\u0131n<\/td>\n<td>\u015eirketin \u00fcr\u00fcnlerini ve \u00fcr\u00fcn hatt\u0131n\u0131 anlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Sipari\u015f t\u00fcr\u00fcn\u00fcz\u00fc belirleyin<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Yat\u0131r\u0131m\u0131n\u0131z\u0131 izleyin<\/td>\n<td>Biyoteknoloji haberlerine s\u00fcrekli dikkat gerektirir<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Pocket Option Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Neden Cazip?<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa yeni ba\u015flayanlar i\u00e7in Pocket Option, borsaya giri\u015fin daha az korkutucu olmas\u0131n\u0131 sa\u011flayan birka\u00e7 avantaj sunar:<\/p>\n<p><strong>Sadece 5 $ minimum depozito<\/strong> ile stratejileri d\u00fc\u015f\u00fck riskle test etmenize olanak tan\u0131r. Bu, fiyatlar\u0131n \u00f6nemli dalgalanmalar g\u00f6sterebildi\u011fi biyoteknoloji gibi volatil sekt\u00f6rler i\u00e7in \u00f6zellikle de\u011ferlidir.<\/p>\n<p><strong>H\u0131zl\u0131 do\u011frulama s\u00fcreci<\/strong> sayesinde hesap a\u00e7\u0131ld\u0131ktan sonra dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flayabilirsiniz. Platform, \u00e7ok \u00e7e\u015fitli kimlik belgelerini kabul ederek eri\u015filebilirli\u011fi \u00f6nceliklendirir.<\/p>\n<p><strong>\u00c7oklu para \u00e7ekme se\u00e7enekleri<\/strong> aras\u0131nda banka transferleri, e-c\u00fczdanlar ve kripto para bulunur; bu da karlar\u0131n\u0131za eri\u015fimde esneklik sa\u011flar. Tercih etti\u011finiz \u00f6deme y\u00f6ntemi ne olursa olsun uygun se\u00e7enekler bulabilirsiniz.<\/p>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ve e\u011fitim kaynaklar\u0131, \u00f6zellikle biyoteknoloji gibi karma\u015f\u0131k sekt\u00f6rlerle u\u011fra\u015f\u0131rken \u00f6\u011frenirken kazanmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te Exelixis: Onkoloji \u0130novasyon Lideri<\/h2>\n<p>Exelixis, kanser tedavisi alan\u0131nda \u00f6nemli bir oyuncu olarak kendini kan\u0131tlad\u0131. \u015eirketin hedefe y\u00f6nelik k\u00fc\u00e7\u00fck molek\u00fcl tedavilerine odaklanmas\u0131 ba\u015far\u0131l\u0131 oldu, \u00f6zellikle \u00e7oklu kanser t\u00fcrlerini tedavi eden amiral gemisi ilac\u0131 Cabometyx ile; b\u00f6brek h\u00fccreli karsinom, karaci\u011fer kanseri ve \u015fimdi de n\u00f6roendokrin t\u00fcm\u00f6rler dahil.<\/p>\n<p>\u015eirketin i\u015f modeli, do\u011frudan \u00fcr\u00fcn sat\u0131\u015flar\u0131n\u0131 Ipsen ve Takeda gibi b\u00fcy\u00fck ila\u00e7 \u015firketleriyle stratejik ortakl\u0131klarla birle\u015ftiriyor. Bu yakla\u015f\u0131m, daha b\u00fcy\u00fck \u015firketlerin da\u011f\u0131t\u0131m a\u011flar\u0131ndan yararlan\u0131rken ara\u015ft\u0131rma ve geli\u015ftirmeye odaklanmalar\u0131n\u0131 sa\u011fl\u0131yor.<\/p>\n<p><strong>2025 i\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: Exelixis, Amerika Birle\u015fik Devletleri genelinde <strong>214 kapsaml\u0131 kanser merkezi<\/strong> ile etkileyici bir i\u015f birli\u011fi a\u011f\u0131na sahip; bunlar\u0131n aras\u0131nda 51 Ulusal Kanser Enstit\u00fcs\u00fc taraf\u0131ndan belirlenmi\u015f merkez bulunuyor. \u0130la\u00e7lar\u0131, 87 akademik t\u0131p merkezi ve 129 toplum hastanesi a\u011f\u0131 arac\u0131l\u0131\u011f\u0131yla hastalara ula\u015f\u0131yor; bu, orta \u00f6l\u00e7ekli bir biyoteknoloji \u015firketi i\u00e7in inan\u0131lmaz bir pazar penetrasyonunu g\u00f6steriyor.<\/p>\n"},"faq":[{"question":"Exelixis, Inc. hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 a\u00e7\u0131p fonlay\u0131n, EXEL hakk\u0131nda ara\u015ft\u0131rma yap\u0131n, uygun sipari\u015f t\u00fcr\u00fcn\u00fc belirleyin ve yat\u0131r\u0131m\u0131n\u0131z\u0131 d\u00fczenli olarak izleyin."},{"question":"EXEL hissesinin 2025 sonu fiyat hedefi nedir?","answer":"Analistlerin ortalama fiyat hedefi 41-44 $ aral\u0131\u011f\u0131nda olup, mevcut seviyelerden %6-14 aras\u0131nda bir y\u00fckseli\u015f potansiyeli \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Exelixis'in en b\u00fcy\u00fck riski nedir?","answer":"Reg\u00fclasyon belirsizli\u011fi, rekabet bask\u0131s\u0131, gelirlerin b\u00fcy\u00fck k\u0131sm\u0131n\u0131n Cabometyx'e ba\u011fl\u0131 olmas\u0131 ve ortakl\u0131k gelirlerindeki dalgalanmalar en \u00f6nemli riskler aras\u0131ndad\u0131r."},{"question":"Yeni ba\u015flayanlar EXEL hissesi i\u00e7in ne yapmal\u0131?","answer":"K\u00fc\u00e7\u00fck bir pozisyonla ba\u015flay\u0131n, fiyat uyar\u0131lar\u0131 kurun, uzun vadeli d\u00fc\u015f\u00fcn\u00fcn ve yat\u0131r\u0131mlar\u0131n\u0131z\u0131 \u00e7e\u015fitlendirin."},{"question":"Pocket Option yeni yat\u0131r\u0131mc\u0131lar i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama s\u00fcreci, \u00e7oklu para \u00e7ekme se\u00e7enekleri ve kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ile yeni ba\u015flayanlar i\u00e7in ideal bir platformdur."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Exelixis, Inc. hisseleri nas\u0131l sat\u0131n al\u0131n\u0131r?","answer":"Bir ticaret platformu se\u00e7in, hesab\u0131n\u0131z\u0131 a\u00e7\u0131p fonlay\u0131n, EXEL hakk\u0131nda ara\u015ft\u0131rma yap\u0131n, uygun sipari\u015f t\u00fcr\u00fcn\u00fc belirleyin ve yat\u0131r\u0131m\u0131n\u0131z\u0131 d\u00fczenli olarak izleyin."},{"question":"EXEL hissesinin 2025 sonu fiyat hedefi nedir?","answer":"Analistlerin ortalama fiyat hedefi 41-44 $ aral\u0131\u011f\u0131nda olup, mevcut seviyelerden %6-14 aras\u0131nda bir y\u00fckseli\u015f potansiyeli \u00f6ng\u00f6r\u00fclmektedir."},{"question":"Exelixis'in en b\u00fcy\u00fck riski nedir?","answer":"Reg\u00fclasyon belirsizli\u011fi, rekabet bask\u0131s\u0131, gelirlerin b\u00fcy\u00fck k\u0131sm\u0131n\u0131n Cabometyx'e ba\u011fl\u0131 olmas\u0131 ve ortakl\u0131k gelirlerindeki dalgalanmalar en \u00f6nemli riskler aras\u0131ndad\u0131r."},{"question":"Yeni ba\u015flayanlar EXEL hissesi i\u00e7in ne yapmal\u0131?","answer":"K\u00fc\u00e7\u00fck bir pozisyonla ba\u015flay\u0131n, fiyat uyar\u0131lar\u0131 kurun, uzun vadeli d\u00fc\u015f\u00fcn\u00fcn ve yat\u0131r\u0131mlar\u0131n\u0131z\u0131 \u00e7e\u015fitlendirin."},{"question":"Pocket Option yeni yat\u0131r\u0131mc\u0131lar i\u00e7in neden uygundur?","answer":"D\u00fc\u015f\u00fck minimum depozito, h\u0131zl\u0131 do\u011frulama s\u00fcreci, \u00e7oklu para \u00e7ekme se\u00e7enekleri ve kullan\u0131c\u0131 dostu aray\u00fcz\u00fc ile yeni ba\u015flayanlar i\u00e7in ideal bir platformdur."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Exelixis, Inc. (EXEL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Exelixis, Inc. (EXEL) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exelixis, Inc. (EXEL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Exelixis, Inc. (EXEL) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-25T10:06:42+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Exelixis, Inc. (EXEL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Exelixis, Inc. (EXEL) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-25T10:06:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/\",\"name\":\"Exelixis, Inc. (EXEL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Exelixis, Inc. (EXEL) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"datePublished\":\"2025-08-25T10:06:42+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exelixis, Inc. (EXEL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Exelixis, Inc. (EXEL) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Exelixis, Inc. (EXEL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Exelixis, Inc. (EXEL) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/","og_locale":"tr_TR","og_type":"article","og_title":"Exelixis, Inc. (EXEL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Exelixis, Inc. (EXEL) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-25T10:06:42+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Exelixis, Inc. (EXEL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Exelixis, Inc. (EXEL) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-25T10:06:42+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/","name":"Exelixis, Inc. (EXEL) Hisseleri Nas\u0131l Al\u0131n\u0131r - Exelixis, Inc. (EXEL) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","datePublished":"2025-08-25T10:06:42+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals13.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-exelixis\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Exelixis, Inc. (EXEL) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Exelixis, Inc. (EXEL) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":346360,"slug":"how-to-buy-exelixis","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Exelixis, Inc. (EXEL) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Exelixis, Inc. (EXEL)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-exelixis\/"},"pt_AA":{"locale":"pt_AA","id":346361,"slug":"how-to-buy-exelixis","post_title":"Como comprar a\u00e7\u00f5es da Exelixis, Inc. (EXEL) - Investimento em a\u00e7\u00f5es da Exelixis, Inc. (EXEL)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-exelixis\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/346356","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=346356"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/346356\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334099"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=346356"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=346356"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=346356"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}